Actinium Pharmaceuticals (ATNM)
(Delayed Data from AMEX)
$1.80 USD
-0.08 (-4.26%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.80 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Actinium Pharmaceuticals, Inc. [ATNM]
Reports for Purchase
Showing records 1 - 20 ( 97 total )
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Shock FDA BLA Feedback Leads to Strategic Realignment of Pipeline; PT Down to $4
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
FDA Greenlights Actinium''s IND for Iomab-ACT Targeted Conditioning in Sickle Cell Disease
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Emerging Synergy; Actimab-A and Menin Inhibitor Preclinical Combo Data are Promising at EHA ''24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
KOL Event Highlights the Clinical and Commercial Opportunities of Iomab-ACT
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Big Pharma''s Activity in the Radio-Therapy Space Hot as Ever
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
1Q24 Results; Steady as She Goes; Radio-Therapeutic Pipeline Continues Towards Key Catalysts
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
2023 Results; Iomab-ACT Clinical Collaboration Enrollment to Begin Pending FDA Review
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Iomab-ACT Looks to Improve CAR-T Therapy in New Clinical Collaboration With UT Southwestern
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Appetite Remains High For Radiopharmaceuticals; We See Actinium As Ripe For Takeout
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
A Glowing Start With Strategic Growth Option For Actinium-225
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
TCT ''24 Presentations Underscore Iomab-B''s Differentiated Efficacy in TP53+ Settings and Beyond
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
ASH Presentation Highlights Iomab-B''s Capacity to Improve Key Outcomes in High Risk TP53+ r/r AML Population
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Actimab-A Exhibits Robust CD33+ Targeting Activity and Disrupts Immunosuppression in Preclinical Experiments
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
3Q23 Results; Iomab-B Strong in TP53+ Patients; BLA Filing on Track for 1H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
A Favorite Under-the-Radar Indication of Ours Gets More NIH Cash; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Pharma Interest in Radiopharma Remains Glowing; Iomab-B BLA Coming Soon
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Extended Survival Data Reaffirms Actimab-A as Potential Backbone Combination Therapy for AML
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
2Q23 Results; Execution Focus; Iomab-B BLA and EAP Launch On Track for 2H23; Price Target Adjusted to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J